January 26, 2022

EMERYVILLE, Calif., January 26, 2022– FLG client, Kyverna Therapeutics (“Kyverna”), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, has announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. FLG partner Jonathan Wolter assisted as CFO. Additional investors included the company’s founding investors Westlake Village BioPartners (“Westlake”), Vida Ventures, and Gilead Sciences (“Gilead”), with new investors RTW Investments, LP (“RTW”), CAM Capital, Insight Partners, HealthCor, LYFE Capital, Intellia Therapeutics, Argentum Peak, Hudson Bay Capital, and jVen Capital.  Proceeds will support initiation of a Phase 2 clinical trial for lead asset KYV-101 in 1H2022 and expand development of engineered allogeneic and autologous T-cell therapies across the spectrum of autoimmune diseases.

Full press release is here.